TORONTO — January 24, 2024 — BioAro Inc. announced its inaugural Longevity Innovation Forum, bringing together leading researchers, clinicians, and investors focused on the future of precision health and longevity medicine.
The roundtable discussion will be moderated by Fady Hannah-Shmouni, MD DABIM FRCPC, clinical endocrinologist, geneticist, and Professor at the University of British Columbia. Dr. Hannah-Shmouni brings expertise at the intersection of genomic medicine, endocrinology, and digital health innovation.
The Forum aims to advance dialogue on evidence-based approaches to extending healthspan, highlighting the convergence of multi-omics diagnostics, AI-driven clinical tools, and personalized therapeutic strategies.
BioAro Inc. is a genomics and precision health company advancing accessible longevity solutions through partnerships with leading healthcare organizations.
Source: PR Newswire, January 24, 2024
